OPTIMI HEALTH CORP
OPTHNASDAQTrading Snapshot
- Day Range
- $4.73 – $4.86
- 52-Week Range
- —
- Volume
- $2.61B
- Avg Volume
- $3.22B
- Shares Outstanding
- 5.7M
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $426,904
- Last Q Revenue
- $98,700
- P/E Ratio
- —
- P/S Ratio
- 163.6x
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- +7.9%
Why Investors Own OPTH
- ✓High-growth profile — revenue up +48.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OPTIMI HEALTH CORP
OPTH
StockOtter · stockotter.spaceAbout OPTIMI HEALTH CORP
Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available for purchase through the Amazon marketplace, via distributors and brokers, and directly online.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Optimi Health Appoints Melanie Pump to Board of Directors
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies Seasoned finance executive brings more than 25 year
Optimi Health Corp. (NASDAQ:OPTH) Stock Short Interest Jumps 109.1%
Optimi Health Corp. (NASDAQ: OPTH - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 20,500 shares, an increase of 1
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedel
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedel
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers Health Canada-authorized trial to evaluate efficacy and safety of two se
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027